drugset / Trial / NCT00328614
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
Phase 1
Completed
32 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Cytogen Corporation · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and effectiveness of Samarium-153 when given in combination with hormonal and external beam radiation therapy in men with high risk prostate cancer.
Timeline
- Start
- 2003-03
- Primary completion
- 2009-02
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Samarium 153 | Unknown | 9.25 mbq/kg | — |
| Subject | Samarium 153 | Unknown | 18.5 mbq/kg | — |
| Subject | Samarium 153 | Unknown | 27.75 mbq/kg | — |
| Subject | Samarium 153 | Unknown | 37 mbq/kg | — |
| Subject | Samarium 153 | Unknown | 55.5 mbq/kg | — |
| Subject | Samarium 153 | Unknown | 74 mbq/kg | — |
| Background | Bicalutamide | Other / unclassified | — | — |
| Background | Goserelin | Other / unclassified | — | — |